OZEMPIC®

Drug Information Related Patent

Hold Company

NOVO

Learn More

Dosage and Administration

SOLUTION;SUBCUTANEOUS

Specification

2MG/1.5ML (1.34MG/ML); 4MG/3ML (1.34MG/ML); 8MG/3ML (2.68MG/ML); 2MG/3ML (0.68MG/ML)

Indication

OZEMPIC® improves glycemic control and reduces the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes and cardiovascular disease as an adjunct to diet and exercise.

Use

Instructions for Use

API

SEMAGLUTIDE

API Structure

We Supply

SEMAGLUTIDE

Note:

In-house Standard/Commerical
Facility GMP
USMF/ASMF/CDE/DMF/CEP/NMPA/FDA/WC

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
8536122	2026/3/20
10335462	2033/6/21
11446443	2025/10/20
9687611	2027/2/27
10376652	2026/1/20
9861757	2026/1/20
9616180	2026/1/20
10357616	2026/1/20
11311679	2026/1/20
9457154	2027/9/27
8920383	2026/7/17
8579869	2023/6/30
9775953	2026/7/17
8684969	2025/10/20
11097063	2026/7/17
RE46363	2026/8/3
9108002	2026/1/20
9132239	2032/2/1
8114833	2025/8/13
10220155	2026/7/17
7762994	2024/5/23

API Patent

Patent No	Expiration Date
8536122	2026/3/20

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.